Sanifit touts positive PhIIb data; REGENXBIO licenses Clearside Biomedical tech
→ Rare disease biotech Sanifit — which in June, raised nearly $81 million in Spain’s largest-ever private biotech fundraise — has announced that its international Phase IIb CaLIPSO study of SNF472 met its primary endpoint. The trial studied patients with end-stage kidney disease (ESKD) on hemodialysis and demonstrated a reduction in coronary artery calcium (CAC) volume in patients treated with SNF472 versus placebo. Detailed data will be presented at a medical conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.